secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001641172-25-021039
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi eliminates President role; approves 1-for-12 reverse stock split effective Aug 5, 2025
--------------------------------------------------------------------------------

- Calidi eliminated the President, Medical & Scientific Affairs position held by Dr. Boris Minev, effective July 29, 2025; CMO Dr. Guy Travis Clifton assumes duties.
- Reverse stock split at 1-for-12 ratio; shares expected to begin trading on split-adjusted basis on NYSE American at market open August 5, 2025.
- Stockholders approved the reverse split on July 9, 2025; Board approved ratio on July 11, 2025; new CUSIP is 320703 408.
- Fractional shares will be rounded up to the nearest whole share; no action required for book-entry or street name holders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225021039/0001641172-25-021039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225021039/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-021039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer